Evidence map›Paper›PMID 21423204›Full record

ArticleOncogene2011

Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo.

L K Mullany, H-Y Fan, Z Liu, L D White, A Marshall, P Gunaratne, M L Anderson, C J Creighton, L Xin, M Deavers and 2 more

Abstract read
In one paragraph

Article in Oncogene, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
11.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 72 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Harnessing preclinical models for the interrogation of ovarian cancer.Journal of experimental & clinical cancer research : CR · 2022
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Thy-1Scientific reports · 2017
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

L K MullanyDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
H-Y Fan
Z Liu
L D White
A Marshall
P Gunaratne
M L Anderson
C J Creighton
L Xin
M Deavers
K-K Wong
J S Richards
Baylor College of Medicine · USThe University of Texas MD Anderson Cancer Center · USUniversity of Houston · US

Funding

TRANSGENIC MOUSE MODELS TO STUDY OVARIAN FUNCTIONU54HD007495 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI MATZUK, MARTIN M. · 1998 to 2013
$19.9M
LH ACTION IN OVARIAN CELL DIFFERENTIATIONR37HD016229 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI RICHARDS, JOANNE S. · 1998 to 2007
$2.0M
LH ACTION IN OVARIAN CELL DIFFERENTIATIONR01HD016229 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI RICHARDS, JOANNE STEWART · 1985 to 2013
$1.9M
LH Action in Ovarian Cell DifferentiationR56HD016229 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI RICHARDS, JOANNE STEWART · 2008 to 2008
$326k
NCI NIH HHS P50 CA08369NICHD NIH HHS HD-16229NICHD NIH HHS R01 HD016229NICHD NIH HHS R37 HD016229NICHD NIH HHS R56 HD016229NICHD NIH HHS U54 HD007495
6 · The paper itself

Abstract

Ovarian cancer is a complex and deadly disease that remains difficult to detect at an early curable stage. Furthermore, although some oncogenic (Kras, Pten/PI3K and Trp53) pathways that are frequently mutated, deleted or amplified in ovarian cancer are known, how these pathways initiate and drive specific morphological phenotypes and tumor outcomes remain unclear. We recently generated Pten(fl/fl); Kras(G12D); Amhr2-Cre mice to disrupt the Pten gene and express a stable mutant form of Kras(G12D) in ovarian surface epithelial (OSE) cells. On the basis of histopathologic criteria, the mutant mice developed low-grade ovarian serous papillary adenocarcinomas at an early age and with 100% penetrance. This highly reproducible phenotype provides the first mouse model in which to study this ovarian cancer subtype. OSE cells isolated from ovaries of mutant mice at 5 and 10 weeks of age exhibit temporal changes in the expression of specific Mullerian epithelial marker genes, grow in soft agar and develop ectopic invasive tumors in recipient mice, indicating that the cells are transformed. Gene profiling identified specific mRNAs and microRNAs differentially expressed in purified OSE cells derived from tumors of the mutant mice compared with wild-type OSE cells. Mapping of transcripts or genes between the mouse OSE mutant data sets, the Kras signature from human cancer cell lines and the human ovarian tumor array data sets, documented significant overlap, indicating that KRAS is a key driver of OSE transformation in this context. Two key hallmarks of the mutant OSE cells in these mice are the elevated expression of the tumor-suppressor Trp53 (p53) and its microRNA target, miR-34a-c. We propose that elevated TRP53 and miR-34a-c may exert negatively regulatory effects that reduce the proliferative potential of OSE cells leading to the low-grade serous adenocarcinoma phenotype.

Indexed as

AnimalsBiomarkers, TumorBlotting, WesternCarcinoma, Ovarian EpithelialCell Line, TransformedCells, CulturedCell Transformation, NeoplasticCystadenocarcinoma, SerousDisease Models, AnimalEpithelial CellsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMiceMice, KnockoutBiomarkers, TumorHras protein, mouseMicroRNAsMIRN34a microRNA, mouseProto-Oncogene Proteins p21(ras)PTEN PhosphohydrolasePten protein, mouseTumor Suppressor Protein p53

Identifiers

PMID21423204
PMCPMC3139785
OpenAlexW2026674119

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.